Yuksekkaya, Hasan A.Arikan, CigdemYazici, AyseBaran, MasallahAydogdu, SemaKilic, Murat2019-10-272019-10-2720091397-31421399-3046https://doi.org/10.1111/j.1399-3046.2008.00944.xhttps://hdl.handle.net/11454/43218SRL is a new and potent immunosuppressive agent that has been successfully introduced in organ transplantation. In contrast to other immunosuppressive agents, SRL has a potent antitumor activity both in vitro and in vivo. Herein, we report a child with Kaposi's sarcoma that was diagnosed 30 months after LDLT and treated successfully with only conversion to SRL monotherapy. KS regressed completely at the end of the first month and remained in remission during 28 months follow-up.en10.1111/j.1399-3046.2008.00944.xinfo:eu-repo/semantics/closedAccessKaposi's sarcomasirolimusimmunosuppressionpediatric liver transplantationArticle133375378WOS:00026489170002018452496Q2Q2